智通财经APP获悉,康宁杰瑞制药-B(09966)尾盘涨幅进一步扩大,截至发稿,涨14.03%,报10.81港元,成交额7386.46万港元。
消息面上,康宁杰瑞制药将于8月28日(下周四)召开董事会会议以审批中期业绩。公司此前预计,上半年取得利润不少于人民币2000万元,去年同期亏损约人民币4490万元。公司于报告期内转亏为盈,主要基于三项授权合作的里程碑收入和商业化产品的销售收入。
此外,康宁杰瑞制药自主研发的程序性死亡配体1(PD-L1)/整合素αvβ6双特异性抗体偶联药物(ADC)JSKN022的新药临床试验申请已获中国国家药品监督管理局药品审评中心正式受理。公司计划开展用于治疗晚期恶性实体瘤的JSKN022首次人体临床研究。目前全球范围内尚无靶向整合素αvβ6或PD-L1的ADC上市,相关在研药物均处于临床研究阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.